Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 8,642 shares, a decline of 55.7% from the February 26th total of 19,488 shares. Approximately 0.5% of the company’s shares are sold short. Based on an average daily volume of 75,768 shares, the short-interest ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Wall Street Zen cut Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Institutional Trading of Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent filing with the Securities and Exchange Commission. 7.06% of the stock is owned by institutional investors.

Indaptus Therapeutics Stock Performance

Shares of NASDAQ INDP remained flat at $1.78 during trading hours on Friday. The company had a trading volume of 7,748 shares, compared to its average volume of 46,686. Indaptus Therapeutics has a 12 month low of $1.52 and a 12 month high of $19.91. The stock has a market capitalization of $3.99 million, a PE ratio of -0.07 and a beta of 0.97. The stock has a 50 day moving average price of $2.00 and a 200-day moving average price of $2.55.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($3.10) earnings per share for the quarter, topping the consensus estimate of ($4.36) by $1.26. On average, equities research analysts anticipate that Indaptus Therapeutics will post -1.79 earnings per share for the current fiscal year.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.